Therefore, we aimed to test an alternative approach that blocks glucocorticoid-induced fatty liver without compromising its beneficial action, given the fact that upregulation of FASN and CD36 is crucial in mediating glucocorticoid-induced fatty liver. The gene discussed is FASN; the disease is Hepatic steatosis.